Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
DREAMM-6: Safety and tolerability of belantamab mafodotin in combination with bortezomib/dexamethasone in relapsed/refractory multiple myeloma (RRMM).
Ajay K. Nooka, Keith Stockerl‐Goldstein, Hang Quach, Adam Forbes, María‐Victoria Mateos, Amit Khot, Alan Tan, Rafat Abonour, Bikramjit Chopra, Rachel Rogers, Geraldine Ferron‐Brady, Jacqueline Davidge, Steve Frey, Anne Yeakey, Mala K. Talekar, Katarina Luptakova, Ira Gupta, Rakesh Popat (2020). DREAMM-6: Safety and tolerability of belantamab mafodotin in combination with bortezomib/dexamethasone in relapsed/refractory multiple myeloma (RRMM).. , 38(15_suppl), DOI: https://doi.org/10.1200/jco.2020.38.15_suppl.8502.
Article277 days agoDREAMM-6: Safety, Tolerability and Clinical Activity of Belantamab Mafodotin (Belamaf) in Combination with Bortezomib/Dexamethasone (BorDex) in Relapsed/Refractory Multiple Myeloma (RRMM)
Rakesh Popat, Ajay K. Nooka, Keith Stockerl‐Goldstein, Rafat Abonour, Ryan Ramaekers, Amit Khot, Adam Forbes, Cindy Lee, Bradley Augustson, Andrew Spencer, María‐Victoria Mateos, Bikramjit Chopra, Rachel Rogers, Deborah A. Smith, Jacqueline Davidge, Rocío Montes de, Geraldine Ferron‐Brady, Anne Yeakey, Mala K. Talekar, Brandon E. Kremer, Ira Gupta, Hang Quach (2020). DREAMM-6: Safety, Tolerability and Clinical Activity of Belantamab Mafodotin (Belamaf) in Combination with Bortezomib/Dexamethasone (BorDex) in Relapsed/Refractory Multiple Myeloma (RRMM). , 136(Supplement 1), DOI: https://doi.org/10.1182/blood-2020-139332.
Article277 days agoCharacterization of NDMM patients treated with daratumumab, lenalidomide, bortezomib and dexamethasone who fail to achieve a VGPR or have early progression
Jonathan L. Kaufman, Efstathios Kastritis, Nisha S. Joseph, Maria Gavriatopoulou, Lilly Gu, Craig C. Hofmeister, Vikas A. Gupta, Evangelos Terpos, Ajay K. Nooka, Sagar Lonial, Meletios A Dimopoulos (2025). Characterization of NDMM patients treated with daratumumab, lenalidomide, bortezomib and dexamethasone who fail to achieve a VGPR or have early progression. , 146(Supplement 1), DOI: https://doi.org/10.1182/blood-2025-407.
Article22 days agoTeclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma
Luciano J. Costa, Nizar J. Bahlis, Aurore Perrot, Ajay K. Nooka, Jin Lu, Charlotte Pawlyn, Roberto Mina, Gastón Caeiro, Alain Kentos, Vânia Hungria, Donna Reece, Ting Niu, Anne K. Mylin, Charlotte T. Hansen, Raphael Teipel, Britta Besemer, Meletios A Dimopoulos, Elena Zamagni, Satoshi Yoshihara, Kihyun Kım, Chang Ki Min, Paul A. F. Geerts, Elena van Leeuwen-Segarceanu, Agata Tyczyńska, Juan Luis Reguera, Magnus Johansson, Markus Hansson, Mehmet Turgut, Mark Grey, Surbhi Sidana, Paula Rodríguez‐Otero, Joaquín Martínez‐López, Hamza Hashmi, Robin Carson, Rachel Kobos, Weili Sun, Kristen Lantz, Anne Seifert, Deborah Briseno-Toomey, Lisa O’Rourke, Ingrid Maria Cecilia Rubin, Diego Vieyra, Lijuan Kang, María‐Victoria Mateos (2025). Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma. , 394(8), DOI: https://doi.org/10.1056/nejmoa2514663.
Article22 days agoPhase 3 randomized study of teclistamab plus daratumumab versus investigator’s choice of daratumumab and dexamethasone with either pomalidomide or Bortezomib (DPd/DVd) in patients (Pts) with relapsed refractory multiple myeloma (RRMM): Results of majestec-3
María-Victoria Mateos, Nizar J. Bahlis, Aurore Perrot, Ajay K. Nooka, Jin Lu, Charlotte Pawlyn, Roberto Mina, Gastón Caeiro, Alain Kentos, Vânia Hungria, Donna Reece, Ting Niu, Anne K. Mylin, Charlotte T. Hansen, Raphael Teipel, Britta Besemer, Meletios A Dimopoulos, Elena Zamagni, Satoshi Yoshihara, Kihyun Kım, Chang‐Ki Min, Paulus A.F. Geerts, Elena van Leeuwen-Segarceanu, Agata Tyczyńska, Juan Luis Reguera, Magnus Johansson, Markus Hansson, Mehmet Turgut, Mark Grey, Surbhi Sidana, Paula Rodríguez‐Otero, Joaquín Martínez‐López, Hamza Hashmi, Richard G. Carson, Rachel Kobos, Weili Sun, Kristen Lantz, Anne Seifert, Debbie Briseno-Toomey, Lisa O’Rourke, Ingrid Maria Cecilia Rubin, Diego Vieyra, Lijuan Kang, Luciano J. Costa (2025). Phase 3 randomized study of teclistamab plus daratumumab versus investigator’s choice of daratumumab and dexamethasone with either pomalidomide or Bortezomib (DPd/DVd) in patients (Pts) with relapsed refractory multiple myeloma (RRMM): Results of majestec-3. , 146(Supplement 2), DOI: https://doi.org/10.1182/blood-2025-lba-6.
Article22 days ago